U

United Therapeutics Corporation

Biotech company develops PAH therapies

Senior Validation Engineer - Equipment

Full-Time
No salary listed
Senior
Bachelor's
Jacksonville, FL, USA
HybridAt least four days per week in the office; this may increase to five days based on business needs.
Biology & BiotechRegulatory & Quality (Life Sciences)

About the job

Requirements
  • Bachelor's degree in a science or engineering field and at least 5 years of relevant validation experience in a medical device or current Good Manufacturing Practice environment.
  • Solid understanding of validation lifecycle principles, industry best practices, and internal policies and procedures.
  • Strong written and verbal communication skills, with the ability to collaborate cross-functionally and communicate validation status, technical information, and data to peers, management, and stakeholders.
  • Ability to work independently with minimal supervision, adapt to changing priorities, and prioritize and manage multiple tasks and projects effectively.
  • Ability to perform, review, and oversee equipment qualification activities.
  • Working knowledge of validation datalogger systems, such as Kaye or Ellab.
  • Working knowledge of applicable regulatory requirements, including Food and Drug Administration and European Union guidelines related to validation and Good Manufacturing Practice activities.
  • Proficiency in standard business and technical software, including word processing, spreadsheets, email systems, and basic statistical tools.
Responsibilities
  • Support the full equipment lifecycle and provide validation and quality engineering support to Manufacturing, Quality Control, Quality Assurance, Operations, and Research and Development.
  • Develop, execute, review, and support approval of validation protocols and final reports for equipment, systems, and processes.
  • Collect, compile, analyze, and interpret validation data to confirm and maintain the validated state of equipment for Good Manufacturing Practice use.
  • Develop, execute, and review validation lifecycle documentation, including Standard Operating Procedures, Validation Master Plans, User Requirements Specifications, Functional Requirements Specifications, Design Specifications, Factory Acceptance Testing, Site Acceptance Testing, and Design Qualification, Installation Qualification, Operational Qualification, Performance Qualification, and Process Validation protocols and reports.
  • Coordinate validation activities and validation plans and tasks, and serve as a technical resource within assigned validation areas.
  • Support contracted resources by providing direction on validation activities and reviewing documentation for compliance with established requirements.
  • Troubleshoot and resolve equipment, system, and process issues using established procedures and sound technical judgment.
  • Perform root cause analysis and apply appropriate problem-solving methodologies.
  • Conduct gap assessments of validation documentation, systems, and practices, communicate findings, and support corrective actions and process improvements.
  • Provide technical guidance and training on validation policies, procedures, and practices to internal and contracted personnel.
  • Evaluate and support change-control activities from a validation perspective, including authoring or reviewing change assessments.
  • Participate in internal and regulatory audits and support audit-readiness activities.
  • Serve as the onsite point of contact for contracted validation services for assigned activities.
  • Maintain equipment and asset data in the Blue Mountain RAM system in alignment with asset lifecycle management requirements.
  • Provide real-time review of manufacturing and service data during scheduled 24/7 availability, with procedure and data review performed remotely when applicable.
  • Review quality-system documentation, including analytical and medical records, batch records, protocols, reports, environmental-monitoring data, Device Design History Files, and laboratory data, for accuracy, completeness, and compliance.
  • Coordinate documentation corrections and continuous-improvement efforts.
  • Provide quality-assurance guidance to internal partners.
  • Perform raw-material review, inspection, and release.
  • Work with internal and external partners to identify areas of improvement and follow projects through completion.
  • Coordinate controlled-document collaboration, review, and approval.
  • Detect quality-system gaps and coordinate their resolution.
  • Perform quality-assurance activities, including deviation and failure investigations, change-control documentation management, complaints, Standard Operating Procedures, and product-quality review.
  • Coordinate the review, creation, and updating of Standard Operating Procedures and reports supporting quality systems.
  • Assist management during Food and Drug Administration and other regulatory-agency inspections.
  • Support the timely and accurate transfer of data, documents, and information to inspectors.
  • Maintain electronic and physical quality-system files, including training records, protocols and reports, environmental-monitoring data, cleaning records, and decontamination records.
Desired Qualifications
  • Working knowledge of computerized information systems and manufacturing control systems, including Building Management Systems, Distributed Control Systems, and Supervisory Control and Data Acquisition systems.

About the company

U

United Therapeutics Corporation

View

United Therapeutics develops therapies for life-threatening diseases, with a focus on pulmonary arterial hypertension and rare conditions. Its approved medicines, including Remodulin, Tyvaso, Orenitram, Adcirca, and Unituxin, treat PAH and pediatric neuroblastoma and are delivered by injections, inhalations, or oral tablets. The company also pursues regenerative medicine and xenotransplantation through its Lung Biotechnology PBC and Revivicor units to create bioengineered organs for transplant. It differentiates itself by combining drug development with organ engineering and by operating as a Public Benefit Corporation that balances profits with social and environmental goals, aiming to extend lives and increase access to transplantable organs.

Company Size

N/A

Company Stage

IPO

Headquarters

Silver Spring, Maryland

Founded

1996

Get referred to United Therapeutics Corporation

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA accepted ralinepag NDA August 2026 and nebulized Tyvaso sNDA September 2026.
  • Q2 2026 net income rose to $333 million; buybacks retired 5.84% shares.
  • Phase 3 ADVANCE OUTCOMES and TETON showed improvement across PAH and IPF programs.

What critics are saying

  • Q2 2026 revenue fell 2%; Tyvaso sales dropped, exposing heavy product concentration.
  • Liquidia’s appeals and labeling fights can still blunt Treprostinil economics by 2027.
  • If ralinepag and IPF filings disappoint FDA, United Therapeutics remains a single-portfolio biotech.

What makes United Therapeutics Corporation unique

  • Martine Rothblatt built United Therapeutics around PAH drugs plus xenotransplantation, with three operating organ sites.
  • September 2026 Delaware ruling strengthened its treprostinil patent moat against Liquidia’s Yutrepia.
  • Stewartville’s August 12, 2026 DPF facility expands gene-edited pig organ production capacity.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • Health Savings Account/Flexible Spending Account
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Time Off
  • Paid Holidays
  • Paid Vacation
  • Parental Leave

Company News

Associated Press
Oct 20th, 2026
United Therapeutics opens third pathogen-free xenograft facility in Houston to scale organ production

United Therapeutics has opened its third Designated Pathogen-Free (DPF) facility, in Houston, Texas. The site produces xenografts, which are animal organs for transplant into humans. The first facility opened in Christiansburg, Virginia, in 2024 to supply clinical trials. The second opened in Stewartville, Minnesota, on August 12, 2026. The Houston and Stewartville sites are built to scale commercial production if regulators approve the products. The facilities use air and water filtration, filtered feed, and decontamination entryways to keep out pathogens. Solar arrays offset a significant part of their energy use. "Every day, people with end-stage organ disease die waiting for an organ that never comes," said chief executive officer Martine Rothblatt. The products remain investigational and are not approved anywhere.

Yahoo Finance
Oct 16th, 2026
Two cash-rich stocks to watch, United Therapeutics and Core Natural Resources, and one to avoid

StockStory has named two cash-generating stocks to watch and one to avoid, arguing that strong cash flow alone does not guarantee good returns. It passes on Simply Good Foods, the maker of Atkins products. Revenue grew 5.2% annually over three years, sales are estimated to fall 9.9% in the next 12 months, and operating margin dropped 31.9 percentage points. The stock trades at $11.12, or 6.5x forward earnings. United Therapeutics, with a free cash flow margin of 34.6%, grew revenue 14.7% a year over five years and posts a 29.1% return on capital. It trades at $541.55, or 18.3x forward earnings. Core Natural Resources, a coal miner with a 6.1% free cash flow margin, grew revenue 15.6% annually over ten years to $4.27 billion. Its shares cost $89.05, or 20.7x forward earnings.

STAT
Oct 14th, 2026
FDA adcomm members' ties to industry under scrutiny.

FDA adcomm members' ties to industry under scrutiny. The FTC going after Martin Shkreli again, a study on GLP-1s and social outcomes, and more biotech news. Oct. 14, 2026 National Biotech Reporter Good morning. Yesterday, we got the devastating news that STAT's infectious disease correspondent, Helen Branswell, passed away. She was a reporter I always looked up to and was also an incredibly generous colleague. Please take the time to read this tribute to her. The need-to-know this morning. * Liquidia and United Therapeutics reached a settlement agreement that resolves their ongoing patent litigation over Liquidia's treatment for pulmonary arterial hypertension. New trial to test effect of GLP-1s on social outcomes. Researchers in Pittsburgh are launching a novel type of GLP-1 trial - testing not only if the drug will help people with addiction, but also if it will help reduce recidivism while improving other employment, health, and housing outcomes. The Center for Addiction Science, Policy and Research (CASPR), a non-profit organizing the effort, and the Allegheny County Department of Human Services are planning to launch the trial in early 2027. They will enroll up to 1,200 adults with alcohol use disorder, opioid use disorder, or both, who are also at high risk of criminal-justice involvement. Half will be randomly assigned to take Novo Nordisk's Wegovy, according to a press release issued yesterday. Your morning rundown of the science, politics, and money driving biotech today

Associated Press
Oct 13th, 2026
Liquidia to pay $380.7M to end all six lawsuits with United Therapeutics

Liquidia has settled all six lawsuits with United Therapeutics, ensuring patients with pulmonary arterial hypertension can keep using its inhaled drug YUTREPIA. The company will pay a net $380.7 million across 2026 and 2027. The deal follows a September 30, 2026, US District Court ruling that Liquidia infringed a United Therapeutics patent covering treatment of a related lung condition. Liquidia will not appeal and has asked to remove that indication from YUTREPIA's label. Payments include $175 million within 30 business days and $145.4 million in two instalments of $72.7 million, due by January 31, 2027, and April 30, 2027. Liquidia will also pay $60.3 million this month to parties with interests in related antitrust litigation. Liquidia reported preliminary third-quarter YUTREPIA net sales of $222.7 million and $396.1 million in cash as of September 30, 2026. It expects to fund the payments without new financing.

BioPharma Watch
Oct 13th, 2026
United Therapeutics presents new data at the CHEST 2026 Annual Meeting.

United Therapeutics presents new data at the CHEST 2026 Annual Meeting. Key Takeaway: United Therapeutics Corporation announced its participation in the CHEST 2026 Annual Meeting, where it will present two oral and five poster presentations. The event, hosted by the American College of Chest Physicians, will take place from October 18-21, 2026, in Phoenix, Arizona. The company aims to highlight its commercial and development portfolio. Market sentiment analysis. Positive factors. * Presentation of new data at a major conference. * Engagement with the medical community through sponsorship. * Diverse portfolio showcased through multiple presentations. BiopharmaWatch analysis. From its catalyst data and publicly available data · not financial advice Best trade, last catalyst 120-day peak, hindsight Typical move average across 6 past catalysts Lead asset NDA/BLA · Pulmonary Arterial Hypertension SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.-(BUSINESS WIRE)-United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that two oral and five poster presentations will be presented across its commercial and development portfolio at the CHEST 2026 Annual Meeting hosted by the American College of Chest Physicians taking place October 18-21, 2026, in Phoenix, Arizona. United Therapeutics will also sponsor and host Time to Look Closer: Emerging Data and Sc Frequently asked questions. What will United Therapeutics present at CHEST 2026? United Therapeutics will present two oral and five poster presentations. When is the CHEST 2026 Annual Meeting? The CHEST 2026 Annual Meeting will take place from October 18-21, 2026. Where is the CHEST 2026 Annual Meeting held? The meeting will be held in Phoenix, Arizona. Who hosts the CHEST 2026 Annual Meeting? The meeting is hosted by the American College of Chest Physicians.